Human Papillomavirus Clinical Trial
— Merck08Official title:
Long Term Immune Memory Responses to Human Papillomavirus (HPV) Vaccination Following 2 Verses 3 Doses of Quadrivalent HPV Vaccine
Verified date | June 2021 |
Source | University of British Columbia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The overall aim of this study is to further understand the memory response to HPV vaccination in subjects who have received 2 versus 3 doses of quadrivalent HPV vaccine. Although memory responses can be detected shortly after immunization, the best approach to measure the long-lasting anamnestic response is to challenge with a booster dose years (> 5) after the original exposure.
Status | Completed |
Enrollment | 18 |
Est. completion date | May 15, 2019 |
Est. primary completion date | May 15, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 17 Years to 35 Years |
Eligibility | Inclusion Criteria: - Written informed consent provided by the participant. - Participant whom the investigator believes can and will comply with the requirements of the protocol. - General good health. - Immunized with Q-HPV vaccine between the ages of 9-13 or 16 to 26 years on the BCGov01 study or the BC provincial program. - Participant who is of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study. Examples of effective methods of birth control include: - Abstinence (no sexual activity) - Hormonal contraceptives including oral, injectable, implants & skin patches - Intrauterine device (IUD) - Male partner sterilization - Male condom combined with a vaginal spermicide (foam, gel, film, cream or suppository) - Male condom combined with a female diaphragm, whether with or without a vaginal spermicide (foam, gel, cream, or suppository) - Adequate contraception does not apply to participants with same sex partners, when this is their preferred and usual lifestyle Exclusion Criteria: - Received more than 3 doses of Q-HPV vaccine - Received any doses of HPV9 vaccine - Systemic hypersensitivity to Q-HPV vaccine or HPV9 vaccine or severe reaction to any previous dose of Q-HPV vaccine. - Receipt of blood or blood product within 3 months prior to Visit 1. - Receipt of a live vaccine within 28 days or an inactive vaccine within 14 days of Visit 1 - Immune compromise resulting from disease or immunosuppressive systemic medication use within 3 months prior to Visit 1. - Inadequate participant fluency in English to provide fully informed consent. - Participant who is currently pregnant or planning a pregnancy during the course of the trial |
Country | Name | City | State |
---|---|---|---|
Canada | Vaccine Evaluation Center, BC Children's Hospital Research Institute | Vancouver | British Columbia |
Lead Sponsor | Collaborator |
---|---|
University of British Columbia | Merck Canada Inc. |
Canada,
Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, Iversen OE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, von Krogh G, Lehtinen M, Paavonen J, Tamms GM, Giacoletti K, Lupinacci L, Esser MT, Vuocolo SC, Saah AJ, Barr E. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007 Jun 21;25(26):4931-9. Epub 2007 Apr 20. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | B Memory Cell Response (% of Memory B Cells That Are Antigen-specific) | To compare the B memory cell populations between girls that received either a primary 2 or 3 dose series, who are then challenged with a subsequent dose after 120 months | At Day 30 post challenge dose of Human Papillomavirus 9-Valent vaccine | |
Primary | Plasmablast Response (% of All B Cells That Are Plasmablasts) | To compare the plasmablast populations between girls that received either a primary 2 or 3 dose series, who are then challenged with a subsequent dose after 120 months | At Day 7 post challenge dose of Human Papillomavirus 9-Valent vaccine | |
Secondary | Variable Gene Usage (Comparison of the Nucleotide Sequences of Antigen-specific Antibody Heavy and Light Chain Variable Region Sequences) | To compare the extent of somatic hypermutation and the variable gene usage between girls that received either a primary 2 or 3 dose series | At Day 7 and Day 30 post challenge dose of Human Papillomavirus 9-Valent vaccine | |
Secondary | Serum Antibody Response (cLIA) - Geometric Mean Titer | To compare the serum antibody responses (cLIA) to HPV 6, 11, 16 & 18 at month 120 in females that received either a primary 2 or 3 dose series, who are then challenged with a subsequent dose | At Day 7 post challenge dose of Human Papillomavirus 9-Valent vaccine | |
Secondary | Serum Antibody Response (cLIA) - Geometric Mean Titer | To compare the serum antibody responses (cLIA) to HPV 6, 11, 16 & 18 at month 120 in females that received either a primary 2 or 3 dose series, who are then challenged with a subsequent dose | At Day 30 post challenge dose of Human Papillomavirus 9-Valent vaccine | |
Secondary | Serum Antibody Response (Total IgG) - Geometric Mean Titer | To compare the serum antibody responses (total IgG) to HPV 6, 11, 16 & 18 at month 120 in females that received either a primary 2 or 3 dose series, who are then challenged with a subsequent dose | At Day 7 post challenge dose of Human Papillomavirus 9-Valent vaccine | |
Secondary | Serum Antibody Response (Total IgG) - Geometric Mean Titer | To compare the serum antibody responses (total IgG) to HPV 6, 11, 16 & 18 at month 120 in females that received either a primary 2 or 3 dose series, who are then challenged with a subsequent dose | At Day 30 post challenge dose of Human Papillomavirus 9-Valent vaccine |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02740790 -
Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 Vaccine in Healthy Females
|
Phase 2 | |
Completed |
NCT01845779 -
Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal
|
N/A | |
Completed |
NCT01422356 -
Human Papillomavirus (HPV) Infection in Young Men Who Have Sex With Men
|
N/A | |
Completed |
NCT01159834 -
Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital)
|
N/A | |
Completed |
NCT02808832 -
An HPV Vaccine Provider Intervention in Safety Net Clinics
|
N/A | |
Completed |
NCT01456715 -
Immunogenicity of Gardasil and Twinrix and the Effect of a Dose of Gardasil or Cervarix Given 42 Months Later.
|
Phase 3 | |
Completed |
NCT02007421 -
Study of the Prevention of Anal Cancer
|
N/A | |
Recruiting |
NCT04708470 -
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
|
Phase 1/Phase 2 | |
Completed |
NCT02267876 -
Longitudinal Clinical Evaluation of the HPV Assay on the BD VIPER LT System With Cervical Specimens
|
||
Recruiting |
NCT01459289 -
Psychosocial Effect of HPV Positivity
|
N/A | |
Completed |
NCT01358097 -
Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy
|
N/A | |
Completed |
NCT01342978 -
Human Papillomavirus (HPV) Oral Transmission Study in Partners Over Time
|
N/A | |
Not yet recruiting |
NCT06434337 -
Evaluation of a Novel Point-of-Care Diagnostic Test for Human Papillomavirus (HPV)
|
||
Active, not recruiting |
NCT02576561 -
Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL
|
Phase 2 | |
Terminated |
NCT02503111 -
The HPV-SAVE Study Team: HPV Screening and Vaccine Evaluation in Men Who Have Sex With Men
|
N/A | |
Recruiting |
NCT02126189 -
The Princess Alexandra Hospital and the QIMR Berghofer Medical Research Institute Head and Neck Cancer Study
|
N/A | |
Completed |
NCT01766284 -
Study of the Diagnostic Efficacy of "Real Time" Niris 1300e Optical Coherence Tomography (OCT) Imaging System in the Management of Pre-invasive and Invasive Neoplasia of the Uterine Cervix
|
N/A | |
Completed |
NCT01524003 -
Chinese Cancer Prevention Study(CHICAPS)
|
N/A | |
Recruiting |
NCT05026138 -
Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)
|
||
Recruiting |
NCT03742869 -
HPV Integration and Tumorigenesis of Uterine Cervical Adenocarcinoma
|